Japan's Mao Shimada became the first figure skater to win three consecutive singles titles at the world junior championships Saturday with a personal-best total in Hungary. The 16-year-old, who led ...

The Las Vegas Raiders made a smart move this offseason after extending un-drafted free agent safety Isaiah Pola-Mao to a two-year contract worth up to $8.45 million. Throughout his first three ...

Daiichi Sankyo is stepping up its interest in RNA therapies, teaming with Nosis Biosciences to design drug candidates capable of reaching targets beyond the liver. The Japanese drugmaker is best ...

The 1977 film Broken Oath marked a change in style for kung fu legend Angela Mao Ying, who glammed it up in a Qing dynasty costume and a “princess” hairstyle to play a ruthless assassin hell ...

AstraZeneca and Daiichi Sankyo's Enhertu has become the first HER2-directed drug to mount a patient survival benefit in a randomized clinical trial in second-line metastatic stomach cancer ...

A father in central China has wowed mainland social media, and even the country’s foreign ministry spokesperson, Mao Ning, for making sophisticated robot toys for his son. “A hardcore dad ...

On March 11, 2025, we remember the profound loss and resilience of the people of Japan following the Great East Japan Earthquake and the Fukushima Daiichi nuclear disaster. Fourteen years later ...

He draws parallels with the chaotic Cultural Revolution ordered by foundational Chinese leader Mao Zedong in 1966, and discusses what strategic openings this could present China.

Just over a decade after being acquired by Daiichi Sankyo, US biotech Plexxikon will be shuttered at the end of March, with its R&D projects transferred to other areas of the Japanese group. It's ...

There has been another twist in the road for the ongoing legal battle between Seagen and Daiichi Sankyo over patent rights for antibody-drug conjugate (ADC) Enhertu. The US Patent and Trademark ...

MSD and Daiichi Sankyo have revealed some of the clinical data that prompted them to start pivotal testing of ifinatamab deruxtecan (I-DXd) in patients with previously treated, extensive-stage ...

Two years after AstraZeneca splashed out $1 billion upfront for rights to Daiichi Sankyo's TROP2-targeting antibody-drug conjugate DS-1062, the drug has generate promising results in advanced non ...